NeurAxis (NRXS) Stock Price, News & Analysis

Company Overview

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept.

Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.

Key Stats

• Today's Range: $2.98 to $3.06
• 50-Day Range: $2.31 to $3.19
• 52-Week Range: $1.33 to $6.20
• Volume: 2,449 shs
• Average Volume: 548,624 shs
• Market Capitalization: $29.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

NeurAxis Stock Analysis - MarketRank™

NeurAxis scored higher than 37% of companies evaluated by MarketBeat, and ranked 750th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeurAxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

NeurAxis has a consensus price target of $7.00, representing about 131.4% upside from its current price of $3.03.

Amount of Analyst Coverage

NeurAxis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeurAxis is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeurAxis is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.64% of the float of NeurAxis has been sold short.

Short Interest Ratio / Days to Cover

NeurAxis has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeurAxis has recently increased by 6.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeurAxis does not currently pay a dividend.

Dividend Growth

NeurAxis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.64% of the float of NeurAxis has been sold short.

Short Interest Ratio / Days to Cover

NeurAxis has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeurAxis has recently increased by 6.76%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeurAxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.40% of the stock of NeurAxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.77% of the stock of NeurAxis is held by institutions.

NRXS Stock Analysis - Frequently Asked Questions

How have NRXS shares performed this year?

NeurAxis' stock was trading at $2.35 at the beginning of 2025. Since then, NRXS shares have increased by 28.7% and is now trading at $3.0250.

How were NeurAxis' earnings last quarter?

NeurAxis, Inc. (NASDAQ:NRXS) posted its earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter. The company had revenue of $0.67 million for the quarter.

When did NeurAxis IPO?

NeurAxis (NRXS) raised $7 million in an initial public offering on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share.

How do I buy shares of NeurAxis?

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeurAxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NRXS
• CIK: 1933567
• Web: neuraxis.com
• Phone: (812) 689-0791
• Fax: N/A
• Employees: 19
• Year Founded: 2011

Price Target and Rating

• Average Price Target for NeurAxis: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +134.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.63 million
• Net Margins: -492.76%
• Pretax Margin: -341.35%
• Return on Equity: N/A
• Return on Assets: -641.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.23

Sales & Book Value

• Annual Sales: $3.22 million
• Price / Sales: 9.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -11.04

Miscellaneous

• Outstanding Shares: 9,873,000
• Free Float: 6,085,000
• Market Cap: $29.42 million
• Optionable: Not Optionable
• Beta: 3.18